中国药物警戒 ›› 2023, Vol. 20 ›› Issue (7): 795-798.
DOI: 10.19803/j.1672-8629.20230047

• 安全与合理用药 • 上一篇    下一篇

辅酶Q10注射剂上市后安全性分析

孟康康1, 刘赛月2   

  1. 1国家药品监督管理局药品评价中心,国家药品监督管理局药物警戒研究与评价重点实验室,北京 100022;
    2浙江省药品不良反应监测中心,浙江 杭州 310012
  • 收稿日期:2023-02-03 出版日期:2023-07-15 发布日期:2023-07-14
  • 作者简介:孟康康,女,硕士,主管药师,药品上市后监测与评价。
  • 基金资助:
    国家科技重大专项重大新药创制(2017ZX091 01001-001-003)

After-marketing safety of coenzyme Q10 for injection

MENG Kangkang1, LIU Saiyue2   

  1. 1Center for Drug Reevaluation, NMPA/NMPA Key Laboratory for Research and Evaluation of Pharmacovigilance, Beijing 100022, China;
    2Zhejiang Center for ADR Monitoring, Hangzhou Zhejiang 310012, China
  • Received:2023-02-03 Online:2023-07-15 Published:2023-07-14

摘要: 目的 分析辅酶Q10注射剂的安全性监测数据,为临床合理用药提供参考。方法 对2004年1月1日至2020年9月30日国家药品不良反应监测数据库、建库至2021年6月30日国内文献数据库中辅酶Q10不良反应/事件报道及国内药品说明书等相关资料进行检索与分析。结果 国家药品不良反应监测数据库收到辅酶Q10注射剂不良反应/事件病例报告3 097例,严重报告320例(占10.4%),严重病例的全身性损害、呼吸系统损害、免疫功能紊乱和感染均显著高于总体病例;应关注辅酶Q10注射剂的严重过敏反应,药品说明书安全性提示不充分。结论 医疗机构应及时关注已发布新修订说明书中更新的安全性信息,严格按照说明书用药;药品生产企业应切实履行药物警戒职责,采取有效风险控制措施,降低药品风险。

关键词: 辅酶Q10注射液, 辅酶Q10氯化钠注射液, 过敏反应, 说明书, 监管措施, 药品不良反应/事件, 安全性, 风险

Abstract: Objective To analyze the data on monitoring of safety of coenzyme Q10 injection and provide reference for clinical rational drug use. Methods Reports of adverse drug reactions/events of coenzyme Q10 injection between January 1, 2004 and September 30, 2020 were retrieved from China adverse drug reaction monitoring database and from domestic literature database between inception to June 30, 2021. And the domestic labeling on Q10 injection were analyzed. Results The national adverse drug reaction monitoring database received 3 097 case reports of adverse reactions/events related to coenzyme Q10 injection, including 320 reports of serious cases(10.4%). Systemic injury, injury to the respiratory system, immune disorders and infections among the severe cases were more serious than among the common cases. Severe allergic reactions to coenzyme Q10 injection deserved more attention. Instructions on safety in the labeling were implicit. Conclusion Medical institutions should keep updated on the safety information in revised instructions and comply with the instructions. Drug manufacturers should be committed to pharmacovigilance and take effective measures to reduce drug risks.

Key words: coenzyme Q10 injection, coenzyme Q10 and sodium chloride injection, allergic reaction, labeling, regulatory measures, adverse drug reaction/event, safety, risk

中图分类号: